Taysha Gene Therapies(TSHA) - 2023 Q4 - Earnings Call Presentation

FORWARD LOOKING STATEMENTS This presentation is intended to be viewed by investors in the U.S. only 2 TSHA-102: Lead Clinical Program in Rett Syndrome • Clinically and commercially proven AAV9 capsid with clinical activity and tolerability across multiple CNS indications • Intrathecal delivery in an outpatient setting targets key CNS regions and minimizes viral load, potentially reducing risk of systemic inflammatory response • Self-complementary technology facilitates more rapid transgene expression Proven ...